Latigo Biotherapeutics, Inc. LTGO

US Pharmaceuticals

$13.32 ▼ -0.22% ($-0.03)

Open $13.22

Prev Close $13.35

Day Range $13.01 – $13.53

52W Range $10.24 – $25.93

Market Cap $885.10M

Beta 0.07

EPS (TTM) $-2.81

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Shares Out.	66,300,000
Website	latigobio.com ↗
Phone	18003464646
Listed	2026-08-07
Revenue	$0
Gross Profit	$0
Net Income	-$20.9M
Total Assets	$408.5M
Total Liabilities	$14.5M
Equity	$394.0M

About Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Latigo Biotherapeutics, Inc. is a publicly traded company under the ticker symbol LTGO on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.